At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Simon Rule (Derriford Hospital, Plymouth, UK) discusses recent advances in the management of mantle cell lymphoma (MCL), including rituximab maintenance after autologous stem cell transplantation in younger patients, bortezomib (Velcade)-based combinations, and lenalidomide as a single agent and in combination with rituximab (R-squared).